Understanding the patient journey in China

Understanding the patient journey in China

2014 and beyond
The Chinese healthcare market is experiencing a period of great change. Utilising local knowledge and detailed case studies, this webinar examines the likely impact on the patient journey and considers the possible implications for market researchers.
 

read more »

Emerging Markets

Director, Marc Yates discusses how to conduct effective research in Emerging Markets

With an increasing focus on emerging markets, there is a greater need for quality data. Director Marc Yates, investigates how to guarantee quality research in Emerging Markets.

read more »

Biosimilars: Friend or foe to healthcare?

Our recent article in February’s Pharma Market Europe and our latest Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000. 

read more »

Assessing HCP/Patient communication in a real-life setting

Our client had a new adherence tool which was to be shortly launched in the Auto-immune market. They wanted to analyse what impact, if any, the tool would have on HCP and Patient communication in a real-life setting in order to inform their marketing strategy

read more »

Big Data—a new player in the Healthcare Industry

Big Data is an exciting by-product of the information technology revolution and offers new ways of understanding customers.

Our previous blog explored the rise of Big Data and its importance to the market research industry. In this blog we investigate some of the ways in which big pharma have used big data and consider the specific implications for us, the healthcare market research industry.
Big data is exciting to healthcare because the integration of data sources, combined with the tremendous volume of data now available, affords pharma the chance to gain fresh insights into patient behavior and HCP decision-making, as well as make improvements to overall health system planning.  Major pharma companies, such as Astra Zeneca and GSK, have been quick to embrace Big Data to gain additional market understanding. For example, Astra Zeneca recently partnered with a data analytics company, Healthcore, which analyses insurance claims. By combining large amounts of medical records with insurance claim data, AZ was able to establish the relationship between treatment effectiveness and cost of care. This helps the company to identify more effective and affordable treatment for patients. This level of analytics, which gives pharmaceutical companies a means of developing more effective pricing strategies, is one that traditional market research agencies are unlikely to be equipped to offer.

read more »